Clinical Efficacy of Osimertinib in Patients with Advanced Non-Small Cell Lung Cancer and Its Effect on Serum CEA and VEGF Expression.

Evid Based Complement Alternat Med · 2022 · PMC9159882 · PMID 35664943

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Discussion In recent years, the incidence of non-small cell lung cancer has shown an increasing trend [ 10 ], and clinical data show that about 50% of cases with NSCLC are over 60 years old, and nearly 30% of patients are over 70 years old [ 11 ].

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.